Nexthera Capital LP lowered its position in shares of Celgene Corporation (NASDAQ:CELG) by 1.6% during the first quarter, Holdings Channel reports. The firm owned 120,000 shares of the biopharmaceutical company’s stock after selling 2,000 shares during the period. Celgene Corporation comprises 7.6% of Nexthera Capital LP’s holdings, making the stock its 4th largest position. Nexthera Capital LP’s holdings in Celgene Corporation were worth $14,932,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. CHURCHILL MANAGEMENT Corp raised its stake in shares of Celgene Corporation by 95.1% in the first quarter. CHURCHILL MANAGEMENT Corp now owns 41,196 shares of the biopharmaceutical company’s stock worth $5,126,000 after buying an additional 20,077 shares during the period. Gibraltar Capital Management Inc. raised its position in shares of Celgene Corporation by 0.9% in the first quarter. Gibraltar Capital Management Inc. now owns 30,206 shares of the biopharmaceutical company’s stock valued at $3,759,000 after buying an additional 271 shares during the last quarter. Hills Bank & Trust Co. raised its position in shares of Celgene Corporation by 2.1% in the first quarter. Hills Bank & Trust Co. now owns 10,763 shares of the biopharmaceutical company’s stock valued at $1,340,000 after buying an additional 218 shares during the last quarter. Boltwood Capital Management raised its position in shares of Celgene Corporation by 13.9% in the first quarter. Boltwood Capital Management now owns 6,770 shares of the biopharmaceutical company’s stock valued at $842,000 after buying an additional 825 shares during the last quarter. Finally, Trust Co raised its position in shares of Celgene Corporation by 2.8% in the fourth quarter. Trust Co now owns 17,135 shares of the biopharmaceutical company’s stock valued at $1,983,000 after buying an additional 465 shares during the last quarter. Hedge funds and other institutional investors own 78.41% of the company’s stock.

Shares of Celgene Corporation (CELG) traded up 0.18% during trading on Friday, hitting $130.61. The company had a trading volume of 2,735,623 shares. The stock has a market cap of $102.18 billion, a PE ratio of 40.45 and a beta of 1.89. Celgene Corporation has a 12-month low of $96.93 and a 12-month high of $139.00. The firm has a 50 day moving average of $134.14 and a 200 day moving average of $124.30.

Celgene Corporation (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.61 by $0.21. The company had revenue of $3.27 billion for the quarter, compared to the consensus estimate of $3.23 billion. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The firm’s quarterly revenue was up 18.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.44 EPS. On average, analysts forecast that Celgene Corporation will post $7.32 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Celgene Corporation (NASDAQ:CELG) Position Cut by Nexthera Capital LP” was first posted by Daily Political and is owned by of Daily Political. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://www.dailypolitical.com/2017/08/12/celgene-corporation-nasdaqcelg-position-cut-by-nexthera-capital-lp.html.

Several brokerages have recently commented on CELG. Cantor Fitzgerald set a $159.00 target price on Celgene Corporation and gave the stock a “buy” rating in a research report on Thursday, April 27th. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $175.00 target price (up previously from $148.00) on shares of Celgene Corporation in a research report on Monday, July 31st. BMO Capital Markets reiterated an “outperform” rating and issued a $160.00 target price (up previously from $152.00) on shares of Celgene Corporation in a research report on Friday, July 28th. Canaccord Genuity set a $156.00 target price on Celgene Corporation and gave the stock a “buy” rating in a research report on Tuesday, June 6th. Finally, BidaskClub upgraded Celgene Corporation from a “sell” rating to a “hold” rating in a research report on Wednesday, June 21st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, twenty-two have given a buy rating and one has assigned a strong buy rating to the company. Celgene Corporation presently has an average rating of “Buy” and a consensus target price of $147.00.

In other news, Director Gilla Kaplan sold 7,500 shares of the stock in a transaction on Wednesday, August 2nd. The stock was sold at an average price of $134.52, for a total value of $1,008,900.00. Following the transaction, the director now owns 76,301 shares of the company’s stock, valued at approximately $10,264,010.52. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Robert J. Hugin sold 175,970 shares of the stock in a transaction on Thursday, June 22nd. The shares were sold at an average price of $134.14, for a total value of $23,604,615.80. Following the completion of the transaction, the insider now directly owns 1,033,909 shares in the company, valued at approximately $138,688,553.26. The disclosure for this sale can be found here. In the last three months, insiders sold 235,255 shares of company stock worth $31,377,042. 0.95% of the stock is currently owned by company insiders.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.